药物与临床碳酸锂联合^(131)I治疗Graves病68例临床探讨  

^(131)I therapy combined with lithium carbonate in 68 cases of Graves disease

作　　者：刘国锋[1] 石光清[2] 何建军[1] 苏见知[1] 

机构地区：[1]中南大学湘雅二医院核医学科,长沙410011 [2]中南大学湘雅三医院核医学科,长沙410013

出　　处：《中南药学》2009年第9期709-710,共2页Central South Pharmacy

摘　　要：目的探讨碳酸锂对Graves甲亢患者甲状腺131I摄取率的影响及监测碳酸锂使用前后血、尿β2-微球蛋白的水平,了解碳酸锂对肾功能的影响。方法对68例131I摄取率<50%的Graves甲亢患者,在给予碳酸锂(250 mg.次-1,3次.d-1)1周前后,分别测定131I摄取率,以观察碳酸锂对131I摄取率的影响及治疗前后血、尿β2-微球蛋白的水平。结果68例患者服碳酸锂1周后,最高131I摄取率达到73.8%,131I摄取率平均由28.5%±11.7%上升至43.4%±18.3%,平均较原有水平提高14.9%±9.4%(P<0.001);而治疗前后血、尿β2-微球蛋白水平无明显变化。结论碳酸锂能有效提高131I摄取率不够高的Graves甲亢患者的131I摄取率,且肾功能正常时,使用碳酸锂1周对Graves病患者肾功能无不良影响。Objective To investigate the lithium carbonate in patients with hyperthyroidism of Graves thyroid ^131I uptake rate and monitoring the effect of lithium before and after the use of blood and urine β2-microglobulin level, and to understand the effect of lithium carbonate on renal function. Methods A total of 68 patients with ^131I uptake rate 50% with Graves hyperthyroidism, after receiving lithium carbonate 250 mg tid, 1 week before and after ^131I uptake were determined. We observed the effect of lithium carbonate on the uptake rate of ^131I and treatment before and after blood and urine β2-microglobulin level. Results One week after lithium carbonate in the patients the maximum rate of ^131I uptake reached 73. 8%, and ^131I uptake rate rose from an average of 28. 5% ± 11.7% to 43.4% ± 18. 3%, 14.9% ± 9.4% higher than before （P 〈0. 001）. There was no significant change before and after the treatment in blood and urine β2-microglobulin level. Conclusion Lithium can effectively improve the ^131I uptake rate in patients with Graves hyperthyroidism. The use of lithium carbonate for 1 week in patients with Graves does not have adverse affect on normal renal function.

关 键 词：碳酸锂 GRAVES病 131I摄取率 肾功能 

分 类 号：R975[医药卫生—药品] R977.1[医药卫生—药学]